All
EnVision Summit 2024: Leadership talk guides women in eye care through personal IPO journey
February 16th 2024Marsha Link, PhD, uses three words—Imagine, Prepare, and Optimize—to encourage women to assess their current leadership journey, strategically plan for advancement, and explore new opportunities for growth and impact in vision care.
FDA approves Eyenovia’s Redwood City commercial manufacturing facility
February 14th 2024According to a news release, the Redwood City, California, site will complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi.
Kyowa Kirin enrolls first patient in phase 2 trial of drops for treatment of diabetic macular edema
February 11th 2024The trial will evaluate tivozanib eye drops (KHK4951), a small-molecule vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3 tyrosine kinase inhibitor (TKI), in patients in with DME.
Study examines the influence of the cellular environment on vision
February 10th 2024Researchers noted a study by Ruhr-University Bochum researchers provides crucial evidence that the ECM influences visual sensory motor behavior already at the retina level, without intervention of disease and/or experimental manipulation.
Kiora Pharmaceuticals announces strategic partnership with Théa Open Innovation
February 7th 2024Under the terms of the agreement, Kiora Pharmaceuticals and Théa Open Innovation will develop and commercialize KIO-301 for the treatment of inherited retinal diseases in a deal valued at up to $301 million.
Mapping the specific progressing anatomic features from drusen to type 3 MNV
February 6th 2024Elodie Bousquet, MD, PhD, and international researchers studied type 3 macular neovascularization (T3 MNV) using optical coherence tomography. In 64.5% of 31 eyes with T3 MNV, it developed over soft drusen, showing drusen growth and outer layer thinning before T3 MNV.